endocrinology
Pheochromocytoma Clinical Probability (10% Rule)
Assesses clinical probability of pheochromocytoma/paraganglioma. Often called the "10% tumor" for its prevalence in syndromic contexts.
Score interpretation
Low clinical suspicion
→ Phaeochromocytoma unlikely; investigate other hypertension causes
Moderate suspicion
→ Biochemical testing: plasma free metanephrines or 24h urine fractionated metanephrines; endocrinology referral
High suspicion
→ Plasma metanephrines urgently; CT/MRI adrenals; alpha-blockade (phenoxybenzamine or doxazosin) before beta-blockade; surgical referral
Interpretation bands for the Phaeochromocytoma Risk. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Metyrapone · Adrenal Steroidogenesis Inhibitor
- Ketoconazole (Adrenal Indication) · Adrenal Steroidogenesis Inhibitor (Antifungal with Adrenal Suppressing Properties)
- Propranolol (Portal Hypertension) · Antihypertensive
- Carvedilol (Portal Hypertension) · Non-Selective Beta-Blocker with Alpha₁-Blocking Activity
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.